BlackRock Inc. Decreases Position in aTyr Pharma Inc (LIFE)

BlackRock Inc. lowered its stake in aTyr Pharma Inc (NASDAQ:LIFE) by 9.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 186,738 shares of the biotechnology company’s stock after selling 20,543 shares during the period. BlackRock Inc.’s holdings in aTyr Pharma were worth $93,000 as of its most recent filing with the SEC.

Separately, Renaissance Technologies LLC grew its stake in aTyr Pharma by 107.4% in the 3rd quarter. Renaissance Technologies LLC now owns 1,107,025 shares of the biotechnology company’s stock valued at $899,000 after buying an additional 573,164 shares during the last quarter. 29.20% of the stock is currently owned by hedge funds and other institutional investors.

LIFE has been the topic of a number of research reports. ValuEngine upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research note on Friday, March 29th. Finally, William Blair reiterated a “market perform” rating on shares of aTyr Pharma in a research note on Tuesday, March 26th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $1.01.

Shares of LIFE opened at $0.62 on Monday. aTyr Pharma Inc has a 52 week low of $0.38 and a 52 week high of $2.50. The stock has a market capitalization of $22.63 million, a P/E ratio of -0.54 and a beta of 2.51. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.25.

aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Monday, March 25th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at

aTyr Pharma Company Profile

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Further Reading: Real Estate Investment Trust (REIT) ETF

Want to see what other hedge funds are holding LIFE? Visit to get the latest 13F filings and insider trades for aTyr Pharma Inc (NASDAQ:LIFE).

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit